Результаты поиска

A Model-Based Meta-Analysis of Pembrolizumab Effects on Patient-Reported Quality of Life: Advancing Patient-Centered Oncology Drug Development.

Pembrolizumab is an immune checkpoint inhibitor that has been approved for more than 20 different indications and has shown great survival benefits in various types of cancer. However, the reported benefits of pembrolizumab in patients' quality of life (QoL) have been inconsistent across different studies and different types of cancer. As oncology drug development increasingly emphasizes patient-centered care, patient-reported outcomes (PROs), particularly patient-reported QoL, are recognized as important clinical endpoints. To characterize the effects of pembrolizumab on patient-reported QoL,

Совпадение в полном тексте источника
… Kim , et al., “ Health‐Related Quality of Life in KEYNOTE‐010: A Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1‐Expressing NSCLC ,” Journal of Thoracic Oncology 14 ( 2019 ): 793 – 801 . 30711649 10.1016/j.jtho.2019.01.016 …

Assessment tools for peripheral neuropathy in multiple myeloma.

Advances in treating multiple myeloma (MM) have improved survival, shifting the management focus toward quality of life. Peripheral neuropathy (PN) is a common treatment-related toxicity that significantly impairs quality of life. However, standardized assessment methods for PN in patients with MM are currently lacking. A comprehensive search of multiple databases (PubMed, Embase, Cochrane Library, and KoreaMed) was conducted to identify relevant records. Eligible studies were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Twenty-

Совпадение в полном тексте источника
… Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy. Int J Clin Oncol. 2012;17:367–372. doi: 10.1007/s10147-011-0303-6. 66. …

Асептический менингит, вызванный моноклональными антителами, используемыми для лечения рака: систематический обзор.

Фон и цель Monoclonal антитела (MAbs) революционизировали лечение рака, но связаны с целым спектром неблагоприятных явлений, включая неврологические осложнения. Понимание механизма и управления осложнениями имеет решающее значение для оптимизации ухода за пациентами. Цель настоящего систематического обзора заключалась в выявлении сообщений о случаях использования МБО для лечения рака, которые привели к появлению асептического менингита (АМ). 2024 (обновлено в мае) 2025). Для оценки качества тематических исследований использовался контрольный перечень критических оценок Института Джоанны Бриггс

Совпадение в полном тексте источника
… Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi: 10.1056/NEJMoa1507643. DOI: 10.1056/NEJMoa1507643. 9. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. …

Targeting HLA-E in Lung Cancer: The Therapeutic Potential of IRF5-Engineered M1-Macrophage-Derived Exosomes.

Immunotherapy is a pivotal approach in the treatment of lung cancer. Although HLA-E is a potential target for tumor immunotherapy, its role in lung cancer remains unclear. Previous studies have identified the transcription factor IRF5 as a characteristic gene of M1-like macrophages, highlighting its crucial role in promoting antitumor immune responses. In this study, we developed an engineered M1-like macrophage exosomes expressing IRF5 (IRF5 M1-exos) and demonstrated their ability to inhibit proliferation, migration, and invasion of lung cancer cells. Moreover, our experiments using a nude mo

Совпадение в полном тексте источника
… Zhao Y., Zheng Y., Zhu Y., Li H., Zhu H., and Liu T., “Docetaxel‐Loaded M1 Macrophage‐Derived Exosomes for a Safe and Efficient Chemoimmunotherapy of Breast Cancer,” Journal of Nanobiotechnology 20 (2022): 359. 20. …

Secondary Primary Cancer after Primary Gastric Cancer: Literature Review and Big Data Analysis Using the Health Insurance Review and Assessment Service (HIRA) Database of Republic of Korea.

Advances in cancer screening and early detection, as well as improvements in surgical techniques and therapeutics, have contributed to decreasing gastric cancer mortality. The number of gastric cancer survivors continues to rise; however, long-term follow-up has revealed an increase in the risk of post-gastrectomy symptoms or other health problems, such as extra-gastric secondary primary cancer (SPC), in these survivors. Therefore, evidence-based screening for new primary cancer is needed in these populations; however, the incidence of SPC varies by country or continent and its characteristics

Совпадение в полном тексте источника
… Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (flot4): A randomised, phase 2/3 trial. …

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab.

BackgroundStandard combination ipilimumab/nivolumab (I/N) is given as 4 induction doses for advanced stage melanoma followed by nivolumab single-agent maintenance therapy. While many patients receive less than 4 doses due to immune-related toxicities, it is unclear if fewer doses of I/N may still provide long term clinical benefit. Our aim is to determine if response assessment after 1 or 2 doses of I/N can predict long-term survival and assess if fewer doses of I/N can lead to similar survival outcomes.MethodsWe performed a retrospective analysis on a cohort of patients with advanced melanoma

Совпадение в полном тексте источника
… Five-Year Outcomes From the Randomized, Phase Iii Trials Checkmate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated non-Small-Cell Lung Cancer . …

A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy.

PurposeChemotherapy-induced peripheral neuropathy is a complex side effect with few available treatment options. The aim of the study was to test the effectiveness of an 8-week course of acupuncture in the management of chemotherapy-induced peripheral neuropathy in cancer patients who were receiving or had received neurotoxic chemotherapy.MethodsRandomized assessor-blinded controlled trial with 2 arms; one arm received acupuncture twice weekly for 8 weeks, while the other arm was a wait-list control group receiving only standard care. Primary outcome was pain intensity and interference over th

Совпадение в полном тексте источника
… .34) | N = 8; 29.4 (3.2) | N = 5; 25.0 (12.4) | N = 13; 27.7 (7.8) Cisplatin-based regimens (mg/m 2 ) ( P = .29) | N = 4; 639.0 (198.0) | N = 3; 500.0 (40.0) | N = 7; 579.4 (160.2) Paclitaxel-based regimen (mg/m 2 ) ( P = .15) | N = 12; 878.1 (279.3) | N = 17; 760.1 (151.9) | N = 29; 809.0 (217.5) Docetaxel-based …

The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Meta-Analysis.

Background: Chemotherapy-induced peripheral neuropathy (CIPN) has no cure, but acupuncture may provide relief through its known neuromodulation or neuroendocrine adjustment. This review aimed to assess the efficacy of acupuncture in treating CIPN. Method: A literature review following the PRISMA Statement was performed, searching 7 databases from inception through August 2019. All studies were clinical trials of the effect of acupuncture on CIPN. The methodological quality of these trials was assessed using Cochrane criteria; meta-analysis software (RevMan 5.2) was used to analyze the data. Da

Совпадение в полном тексте источника
… standardized acupuncture protocol over 8 weeks | PNQ | Acupuncture is superior than control with regard to PNQ ( P = .01) FACT-NTX | FACT-NTX ( P = .002) EORTC QLQ-CIPN20 | EORTC QLQ-CIPN20 ( P = .01) BPI-SF | BPI-SF ( P = .01) Greenlee et al, 32 RCT | 63/USA/English | Breast cancer/taxane (paclitaxel and docetaxel …

Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.

Metabolic alterations, a hallmark of cancer, enable tumor cells to adapt to their environment by modulating glucose, lipid, and amino acid metabolism, which fuels rapid growth and contributes to treatment resistance. In primary breast cancer, metabolic shifts such as the Warburg effect and enhanced lipid synthesis are closely linked to chemotherapy failure. Similarly, metastatic lesions often display distinct metabolic profiles that not only sustain tumor growth but also confer resistance to targeted therapies and immunotherapies. The review emphasizes two major aspects: the mechanisms driving

High-dose vitamin C: A promising anti-tumor agent, insight from mechanisms, clinical research, and challenges.

Vitamin C, also known as ascorbic acid, has sparked controversy since it first emerged as a potential anti-cancer agent. However, an increasing number of preclinical studies have demonstrated that high-dose vitamin C exhibits selective anti-tumor effects, including "pro-oxidative cytotoxicity", "anti-cancer epigenetic regulation", and "immune modulation". Consequently, vitamin C has reemerged as a promising anti-cancer therapy in the form of high-dose administration. Advancements in pharmacokinetic research have facilitated the development of clinical trials. Early clinical studies across vari

Совпадение в полном тексте источника
… However, a phase II randomized trial comparing docetaxel versus docetaxel plus HDVC in patients with metastatic castration-resistant prostate cancer was terminated after an interim analysis indicating the ineffectiveness of the primary endpoints. …

MTAP-Null Tumors: A Comprehensive Review on Synthetic Vulnerabilities and Therapeutic Strategies.

Homozygous deletion of the 9p21.3 genomic locus spanning the CDKN2A/B and MTAP genes is an event affecting 15% of cancers. While CDKN2A is a well-established tumor suppressor gene, the role of MTAP in tumorigenesis varies across cancer types. MTAP codes for methylthioadenosine phosphorylase, a key enzyme in the methionine salvage pathway, and its loss has been associated with several downstream synthetic vulnerabilities. Despite multiple efforts to exploit MTAP loss for targeted therapies, none of these efforts have yielded substantial results in clinical trials. In this review, we consolidate

Совпадение в полном тексте источника
… metastatic solid tumors with MTAP deletion | 80 estimated | DLT, AE, RP2D | [ 133 ] AMG193 and IDE397 | PRMT5 and MAT2A | NCT05975073 | 1/2 | Active, not recruiting | 31 July 2025 | Advanced MTAP-null solid tumors | 53 | Part 1: DLT, TEAE, SAE Part 2: OR, RECIST | [ 134 ] AMG193 alone or in combination with docetaxel … A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-null Solid Tumors. …

Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives.

MicroRNAs (miRNAs) are short (18-25 nt), non-coding, widely conserved RNA molecules responsible for regulating gene expression via sequence-specific post-transcriptional mechanisms. Since the human miRNA transcriptome regulates the expression of a number of tumor suppressors and oncogenes, its dysregulation is associated with the clinical onset of different types of cancer. Despite the fact that numerous therapeutic approaches have been designed in recent years to treat cancer, the complexity of the disease manifested by each patient has prevented the development of a highly effective disease

Совпадение в полном тексте источника
… On the other hand, docetaxel (DTX) is a chemotherapeutic drug that promotes cell cycle arrest, impaired mitosis, and apoptosis. However, this agent possesses low solubility in water, a fast body clearance rate, non-specific biodistribution, and can generate drug resistance. …

Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.

As new molecular tracers are identified to target specific receptors, tissue, and tumor types, opportunities arise for the development of both diagnostic tracers and their therapeutic counterparts, termed "theranostics." While diagnostic tracers utilize positron emitters or gamma-emitting radionuclides, their theranostic counterparts are typically bound to beta and alpha emitters, which can deliver specific and localized radiation to targets with minimal collateral damage to uninvolved surrounding structures. This is an exciting time in molecular imaging and therapy and a step towards personal

Совпадение в полном тексте источника
… Non-responder to Hormonal therapy and Docetaxel. (A) Ga-68-PSMA MIP image showing PSMA-avid disease in skeleton. … Non-responder to Hormonal therapy and Docetaxel. (A) Ga-68-PSMA MIP image showing PSMA-avid disease in skeleton. …

Novel therapies emerging in oncology to target the TGF-β pathway.

The TGF-β signaling pathway governs key cellular processes under physiologic conditions and is deregulated in many pathologies, including cancer. TGF-β is a multifunctional cytokine that acts in a cell- and context-dependent manner as a tumor promoter or tumor suppressor. As a tumor promoter, the TGF-β pathway enhances cell proliferation, migratory invasion, metastatic spread within the tumor microenvironment and suppresses immunosurveillance. Collectively, the pleiotropic nature of TGF-β signaling contributes to drug resistance, tumor escape and undermines clinical response to therapy. Based

Совпадение в полном тексте источника
… Gem/docetaxel Chemotherapy (Part A) + Temozolomide/ Irinotecan II (Part B) NCT03842865 Vigil Vaccine Expanded Access Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Advanced Solid Tumors including Ewing's sarcoma, Ewing's tumor metastatic, Ewing's sarcoma metastatic … Gem/docetaxel | Chemotherapy | | | | (Part A) | + Temozolomide/ Irinotecan | | | | II | (Part B) NCT03842865 | Vigil | Vaccine | Expanded Access Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Advanced Solid Tumors including Ewing's sarcoma, Ewing's tumor …

Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells.

Cancer recurrence remains a great fear for many cancer survivors following their initial, apparently successful, therapy. Despite significant improvement in the overall survival of many types of cancer, metastasis accounts for ~90% of all cancer mortality. There is a growing understanding that future therapeutic practices must accommodate this unmet medical need in preventing metastatic recurrence. Accumulating evidence supports dormant disseminated tumor cells (DTCs) as a source of cancer recurrence and recognizes the need for novel strategies to target these tumor cells. This review presents

Совпадение в полном тексте источника
… CXCR4 Inhibition With AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy. Neoplasia (2012) 14(8):709–18. 10.1593/neo.12324 125. Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, et al. …

Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.

Chemokines are a large family of small chemotactic cytokines that coordinates immune cell trafficking. In cancer, they have a pivotal role in the migration pattern of immune cells into the tumor, thereby shaping the tumor microenvironment immune profile, often towards a pro-tumorigenic state. Furthermore, chemokines can directly target non-immune cells in the tumor microenvironment, including cancer, stromal and vascular endothelial cells. As such, chemokines participate in several cancer development processes such as angiogenesis, metastasis, cancer cell proliferation, stemness and invasivene

Совпадение в полном тексте источника
… | Breast cancer | [ 116 ] CXCR2 | Navarixin + MEK inhibitor | Melanoma | [ 117 ] SB225002 + Sorafenib | Ovarian cancer | [ 118 ] SB225002 + Cisplatin | Lung cancer | [ 119 ] Reparixin + 5-FU | Gastric Cancer | [ 120 ] AZ13381758 + Gemcitabine | Pancreatic ductal adenocarcinoma | [ 121 ] SB265610 + Docetaxel … was able to reduce metastasis and substantially improved life span in a pancreatic ductal adenocarcinoma model, when combined with gemcitabine [ 121 ], while in a prostate cancer model, CXCR2 inhibition by SB265610 was able to limit tumor growth by decreasing myeloid cell infiltration and enhancing Docetaxel-induced …

Critical considerations for targeting colorectal liver metastases with nanotechnology.

Colorectal cancer remains a significant cause of morbidity and mortality worldwide. Half of all patients develop liver metastases, presenting unique challenges for their treatment. The shortcomings of conventional chemotherapy has encouraged the use of nanomedicines; the application of nanotechnology in the diagnosis and treatment of disease. In spite of technological improvements in nanotechnology, the complexity of biological systems hinders the prospect of nanomedicines being applied in cancer therapy at the present time. This review highlights current biological barriers and discusses aspe

Совпадение в полном тексте источника
… It was demonstrated that delivery of imatinib caused a significant reduction in tumor IFP, when combined with docetaxel and quercetin in NPs (Gao et al., 2017 ). …

Classic Kaposi Sarcoma: Current Treatment Strategies and Emerging Therapeutic Approaches.

Classic Kaposi sarcoma (CKS) is a rare vascular neoplasm driven by infection with Kaposi sarcoma-associated herpesvirus (KSHV) and characterized by a heterogeneous geographic distribution. While the etiology of other Kaposi's sarcoma (KS) variants is well established, the underlying mechanisms of CKS appear multifactorial, with several risk factors, among which advanced age and male sex are most significant. Due to the rarity of CKS and its often indolent clinical course, clinical trials are sparse, and current knowledge of therapeutic approaches remains limited. Most available clinical trials

Совпадение в полном тексте источника
… Docetaxel has been less extensively studied but has demonstrated objective response rates of up to 40% [ 57 ]. Neutropenia represents the main dose-limiting toxicity, along with fatigue and peripheral neuropathy [ 58 ]. …

Emerging Research and Future Directions on Doxorubicin: A Snapshot.

Doxorubicin, a widely used anthracycline antibiotic, has been a cornerstone in cancer chemotherapy since the 1960s. In addition to doxorubicin, anthracycline chemotherapy medications include daunorubicin, idarubicin, and epirubicin. For many years, doxorubicin has been the chemotherapy drug of choice for treating a broad variety of cancers. Despite its efficacy, doxorubicin therapy is hindered by serious side effects, primarily cardiotoxicity, and the challenges of drug resistance. Recent research has focused on optimizing doxorubicin's therapeutic index by developing cardioprotective strategi

Совпадение в полном тексте источника
… For instance, combining doxorubicin with taxanes like paclitaxel or docetaxel has demonstrated improved response rates and survival outcomes in breast cancer and other solid tumors [ 36 , 37 ]. …

Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti-cancer agents.

BACKGROUND: The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio-oncology has received increasing attention owing to the cardiotoxic effects of anti-cancer therapies. OBJECTIVES: We aimed to evaluate the clinical characteristics and outcomes of patients with heart failure (HF) who received chemotherapy compared with those of a matched cohort with HF who did not receive chemotherapy, using real-world HF data. METHODS: This study was based on the Diagnosis Procedure Combination (DPC) databas

Совпадение в полном тексте источника
… Anti‐microtubule agents called taxanes are associated with treatment‐induced CV toxicity. 20 For chemotherapy in patients with breast cancer, taxanes are typically combined with anthracyclines, such as docetaxel, after adriamycin + cyclophosphamide (AC) therapy in adjuvant chemotherapy. 18 Although combination …